The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) patients was lacking. 310 patients of advanced NSCLC with common EGFR mutation receiving first-generation EGFR-TKI monotherapy or with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scott, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924189/
https://www.ncbi.nlm.nih.gov/pubmed/35292755
http://dx.doi.org/10.1038/s41598-022-08449-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924189/
https://www.ncbi.nlm.nih.gov/pubmed/35292755
http://dx.doi.org/10.1038/s41598-022-08449-w

Ejemplares similares